CBG (cannabigerol), a new ready-to-use cannabinoid, joins the 1 class of cannabinoids
There are 130 types of cannabinoids, useful and listed in marijuana. THC and CBD are in the spotlight of then, but there are 83 others that are not inactive, and that can also greatly improve your health, including CBG (cannabigerol) finally ready for use.
One of these unknown cannabinoids, but will soon make noise is cannabigerol (CBG). Cannabigerol is an active ingredient in cannabis that is thought to have anti-bacterial properties. CBG has also been proven as inhibiting the capture of GABA. This causes a relaxation effect normally associated with CBD.
Cannabigerol (CBG) is a cannabinoid non-psychoactive which plays an important role in the biochemistry of cannabis. GBC acts as a chemical precursor to other cannabinoids such as THC and CBD. This Conversion usually takes place 6-8 weeks in the flowering cycle. CBG is present only in trace amounts in most cannabis strains, but some strains of hemp are specifically grown to generate higher yields of this cannabinoid. But most of the strains found on the market only contain about 1% of this cannabinoid.
However, CBG has triggered new research on cannabinoids. These envisage possible far broader implications. Today two different medical companies are ready to deliver their CBG-based product, completing a new database on the properties of Cannabigerol.
CBG the neuroprotective cannabinoid
A survey reveals that CBG is highly active in repairing the protective cells of the brain. In 2015, researchers from the Department of Biochemistry and Molecular Biology of the Complutense University of Madrid in Spain, CBG has been found to have neuroprotective properties.
CBG is highly active, improves motor deficits and preserves neurons. But, the powerful neuroprotective cannabigerol, is also an anti-inflammatory agent. This is confirmed by another study of Journal of Neuroimmune Pharmacology, which found its effect on multiple sclerosis.
Relieves neuropathic pain
CBG is therefore promising to relieve neuropathic pain. A message from Otsuka Pharmaceutical et GW Pharma tells us that cannabigerol and other cannabinoids (CBC, CBDV and THCV) help to reduce the symptoms of neuropathic pain (in mice). CBG helped these mice recover from pain caused by surgically induced nerve damage.
Namely that neuropathic pain, is generally refractory to opioids ... In addition to low doses were necessary to relieve pain in these mice. Cannabigerol is therefore effective for the treatment of neuropathic pain. All these studies show that CBG remains very promising, whether used alone or in combination with other cannabinoids.
The study of CBG and other Cannabinoids is essential to understanding the overall effects of cannabis health. Theentourage effectThis synergistic THC, CBD, as well as the main Cannabinoids and terpenes used for health, interact with our body, and also separately with other components.
CBG can also reduce intraocular pressure in the case of glaucoma, and may even be effective in treating nausea and vomiting. CBG has multiple anti-inflammatory effects that could be useful in diseases of the gut just like other cannabinoids. They all come naturally from the cannabis plant. And to be more precise, this same cannabis plant is ready like the CBG for a medical job, on a large scale ...
CBG-A: The mother of cannabinoids
The "g" in CBG-A should be considered informally to mean "genesis". This unique cannabinoid is the chemical source of many others, including all those mentioned above. In fact, cannabis would have no euphoric value and would have very little medicinal value without these particular cannabinoids.
CBG-A is a special acidic precursor that gives rise to therapeutic cannabinoids for a wide range of diseases and conditions, from arthritis to Crohn's disease and cancer. In fact, a study conducted in Israel in 2013 found that cannabis puts Crohn's disease in complete remission in about 50% of cases.
In the world of botany and biology, chemicals produce chemicals. The molecules are transformed under certain conditions, such as heat, light and oxidation, to become cousins slightly modified on their own. Although their new chemical structure may be only slightly different, it is often sufficient to cause a dramatic change in medicinal efficacy in patients or a different psychoactive effect in adult users.
Acidic precursors are slightly different versions of cannabinoids that, under the right conditions, are transformed into the familiar molecules used to treat or provide euphoria for millions of patients. Take the THC, for example. It is the most common cannabinoid and the most abundant (by volume) in most strains of cannabis. It is created by its acid precursor, THC-A (sometimes called THCA or THCa).
When heat is applied to the THC-A, for example from the flame of a lighter during smoking or the flow of hot air produced by a vaporizer, this precursor drops a cluster of carbon dioxide (COO ) to become the most preferred molecule of all, THC (this process is called decarboxylation because it cuts out a carbon and two oxygens).
Similarly, CBD, CBC and CBG are also created by acidic precursors: CBD-A, CBC-A and CBG-A, respectively. All these acidic precursors are themselves derived from CBG-A. In this regard, CBG-A is the mother of many critical and medicinal cannabinoids. In fact, CBG-A is indirectly responsible for a wide range of positive medical therapies, including the following:
- Anti-cancer: THC-A, CBD-A, THC, CBD, CBC, CBC, CBG
- Analgesic (Analgesic): CBG-A, THC, CBD, CBC, CBC, CBG
- Anti-inflammatory: THC-A, CBD-A, CBC-A, THC, CBD, CBC, CBN-A, CBN-A, CBN
- Anti-spasmodic: THC-A, THC, THC, CBD
- Appetite Stimulant: THC
- Suppressor of appetite: THCV
- Bone Stimulant: THC-A, THCV, CBD, CBDV, CBC, CBC, CBG
- Bronchodilator: THC
- Sleep aids (anti-insomnia): CBD, CBC, CBN
Two companies involved
Medical Marijuana Whistler Corporation based in canada, has announced that it plans to release a new cannabis extract from a plant with a "unique phenotype", which is both rich in CBG and THC. This is somewhat unusual, since CBG is usually found in higher amounts in hemp than in marijuana flowers (buds).
This concentrate will be distributed to patients registered with WWMC. This in the hope of learning more about the therapeutic effects of CBG. Especially when this cannabinoide is consumed in the company of THC.
"We are extremely pleased to offer CBG to our patients. And we hope it will expand a lot of conditions "WWMC
Basic research has indicated that CBG has a variety of effects in a cell culture and on (laboratory) animals. It acts as an anti-inflammatory, analgesic and antifungal. CBG is currently under investigation for possible treatment for many disorders. It will be found in cancer treatment, glaucoma, and inflammatory bowel disease. CBG would also seem useful for neurovegetative diseases such as Huntington's disease.
Earlier this year, another company launched a CBG-based product. It is the company Axim Biotechnologies based in the Netherlands. The AX-1602 is prescribed for a clinical test . This one to treat skin diseases, such as psoriasis and eczema.
Axim claims that CBG has shown tremendous efficacy as an anti-inflammatory. It demonstrates several health benefits such as the ability to "slow down" the proliferation of tumor cells in vitro and in vivo.
The chemistry of cannabis can become complex and confusing for the layman. However, a little bit of knowledge about the role of some dominant cannabinoids can be helpful in understanding plant therapy and why it is considered by many to be such a powerful drug that is almost completely devoid of addiction or harmful side effects.